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The efficacy of biologic or conventional systemic thera-
pies for psoriasis has been shown in randomized control-
led trials. Effectiveness, however, has been studied in 
daily practice cohorts, and no aggregation of effective-
ness data is available. This systematic review searched 
PubMed and EMBASE and summarized the real-world 
evidence on effectiveness of biologics (adalimumab, eta-
nercept, infliximab and ustekinumab) and conventional 
systemic therapies (acitretin, cyclosporine, fumarates 
and methotrexate) for the treatment of plaque psoria-
sis in adults. Thirty-two studies were included. Few data 
were available on infliximab, ustekinumab and conven-
tional systemics. Results show that biologics and conven-
tional systemics were effective in real-life treatment of 
psoriasis, with large ranges in the percentage of patients 
reaching 75% improvement in psoriasis area and seve-
rity index score compared with baseline, especially for 
etanercept and adalimumab treatment. Combination 
therapies of biologics with conventional systemics, and 
dose adjustments of biologics were frequently applied 
strategies and may explain the large range in improve-
ments between cohorts. Key words: psoriasis; effective-
ness; biologics; conventional systemic agents; registries; 
daily practice.
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Psoriasis is a common chronic skin disease, with a 
prevalence of 2–4% (1). Different therapeutics have 
been developed to treat this burdensome disease (2–4). 
Randomized controlled clinical trials (RCTs) have ana-
lysed the efficacy of biologic agents (adalimumab, eta-
nercept, infliximab and ustekinumab) and conventional 
systemic therapies (acitretin, cyclosporine, fumarates 
and methotrexate) (5–7). Effectiveness data from real-
life, observational studies, however, are of added value, 
since patients and treatment strategies in daily practice 
differ substantially from those in RCTs (8). The aim of 
this study was to systematically search the literature to 
provide an overview of the current evidence on the ef-
fectiveness in daily practice of biologic and conventional 
systemic therapies for the treatment of adults with plaque 
psoriasis. Short-term (week 12–16), intermediate-term 
(> 16–≤  28 weeks) and long-term (≥ 1 year) Psoriasis 
Area and Severity Index (PASI) responses were investi-
gated. The primary objective was to show the proportion 
of patients that reached PASI75 (a 75% reduction in PASI 
score) with biologic and/or conventional systemic agents 
at week 12–16.
MATERIALS AND METHODS
A systematic literature search was performed on the effective-
ness of treatment with biologics or conventional systemics in 
patients with plaque psoriasis in daily practice. Inclusion and 
exclusion criteria are described in Table SI1. The decision was 
arbitrarily made to exclude studies in which the number of 
patients included at baseline was < 30, since in these articles 
the influence of every additional patient reaching PASI75 has 
a large influence on the total percentage. 
Outcomes
The following outcome measures were chosen (9): (i) PASI 
(10); (ii) Physician’s Global Assessment (PhGA) on a scale of 
0–5, 0–6 or 0–7 (11); and (iii) body surface area (BSA) (11). 
Primary outcome. The primary outcome was the PASI75 score 
for biologic and conventional systemic agents in daily clinical 
practice at week 12–16. 
Secondary outcomes. Secondary outcome measures were 
PASI75 with intermediate-term (17–28 weeks) and long-term 
(≥ 1 year data) treatment, as well as PASI50, PASI90, PASI100 
and decrease in mean PASI, PhGA and BSA with short-, inter-
mediate- and long-term treatment.
All measures were compared with baseline except if stated 
otherwise.
Search strategy
Two electronic databases (Pubmed and EMBASE) were sys-
tematically searched, and studies from 1990 until May 2014 
were included. The term “psoriasis” was combined with terms 
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for study design, treatments of interest and outcome measures 
for effectiveness (Table SII1). 
Data extraction
Two authors (JZ and MEO) independently screened titles and 
abstracts, and checked full articles for inclusion and exclusion 
criteria as well as references for other eligible studies. Data 
were extracted from text, tables or as numbers in figures and 
are shown in Table SIII1. Any differences in decisions about in-
clusion or extraction were resolved by consensus or discussion 
with a third author (EdJ). The results for PASI75 were divided 
into cohorts using monotherapy and cohorts combining biologic 
with conventional systemic treatments in some or all of the 
patients during the study period, prospective vs. retrospective 
and short-, intermediate- and long-term results of treatment. 
PASI75 from per protocol analyses are shown. Comparative 
studies are described in a separate section. 
RESULTS
A total of 32 articles were included (Fig. 1): 28 on 
biologics, 3 on conventional systemic therapies, and 
1 describing both biologic and conventional systemic 
treatment (Table SIII1). Seven articles reported results 
of adalimumab therapy, 20 of etanercept, 4 of inflixi-
mab, 4 of ustekinumab, 1 of acitretin, 2 of fumarates, 
1 of cyclosporine and 3 of methotrexate. There were 
12 prospective and 20 retrospective studies. Results 
from comparative studies and dosing of biologics are 
described below in separate sections. For all effective-
ness results the reader is referred to Table SIII1. 
Biologic therapies
Twenty-eight articles (12–39) reported data on biologic 
therapies and one article (40) compared biologic and 
conventional systemic treatment. For adalimumab the 
mean baseline PASI scores of patient cohorts ranged 
from 10.9 to 20.1, for etanercept these ranges were 
11.3–25.6, for infliximab 14.7–17.7, and for ustekinu-
mab 9.6–22.9. 
Adalimumab
Study characteristics. Of the 7 articles studying the ef-
fectiveness of adalimumab, 3 were prospective (13, 17, 
18) and 4 retrospective studies (12, 14–16), including 
a total of 461 patients. In the study of Van Lümig et al. 
(13), only those patients whose treatment with etaner-
cept had failed and who had switched to adalimumab 
were included, and thus they represented a highly se-
lected patient group. The results from this study were 
therefore not included for data aggregation. Dosing 
regimens varied amongst studies, as well as naïvety 
for biologics, and the number of patients using adali-
mumab in combination with a conventional systemic 
agent. One retrospective study (12) reported the results 
of adalimumab monotherapy. All 7 studies (12–18) 
reported on long-term therapy results. In all 7 studies 
(12–18) conventional systemic agents were allowed, but 
no specification was made of the duration and dosages 
used. Combination with a conventional systemic was 
used in 7–41% (12–18) of patients. Methotrexate was 
used most often. In all studies, the induction dose was 
per license (80 mg at the start and 40 mg at week 1). 
The maintenance dose was 40 mg every other week for 
most patients. However, in all studies dose adjustments 
were allowed. A dose increase to 40 mg weekly or 40 
mg every 10 days was made in 2–36% (12, 14–16, 18) 
of patients. In 2 studies, the mean weekly dose of ada-
limumab was 23 mg (13) and 24 mg (17), respectively. 
In 2 studies (17, 18), a total of 46 patients were treated 
with 40 mg per 3–4 weeks. The mean duration of dose 
increases/decreases were not mentioned.
PASI75 outcome for adalimumab. Overall, PASI75 was 
attained by 27–68% with short-term, 31–82% with 
intermediate-term and 44–89% with long-term (1 and 
2 year) adalimumab treatment (Table SIII1). 
Adalimumab monotherapy. In the one retrospective 
study (12), adalimumab reached PASI75 percentages of 
38% at week 16, 62% at week 24 and 69%  at one year.
Cohorts using adalimumab with conventional systemic 
treatments. PASI75 results from prospective studies 
were 27–54% (17, 18) at week 12, 31% (17) at week 24, 
and 44% (17) at 2 years of adalimumab treatment. In 
retrospective studies, 56–68% (12, 14–16) of patients 
reached PASI75 at week 16 (of which only one study 
(14) used licensed dosing), 50–82% (12, 14–16) at 
week 24, 48–89% (12, 14–16) at 1 year and 83% (16) 
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Etanercept
Study characteristics. Twenty articles studied etaner-
cept therapy in daily clinical practice (Table SIII1). 
Nine studies (13, 18, 20, 22, 24, 26, 32, 33, 35) were 
prospective and 11 retrospective (19, 21, 23, 25, 27–31, 
34, 40), including a total of 2,079 patients. Five of 20 
articles (21, 25, 29, 31, 40) reported results on etaner-
cept monotherapy. In 7 studies (13, 21, 25, 27, 30, 33, 
40) all patients were naïve for biologics, in 12 articles 
a proportion of patients was non-naïve for biologic 
therapy. In one article (28) a highly selected group of 
patients was treated with etanercept, since all patients 
switched from efalizumab therapy. Results from this 
study were not included for data aggregation, but can be 
found in Table SIII1. Dosing regimens varied amongst 
studies. It was explored whether PASI75 results dif-
fered between cohorts using either 50 mg biweekly 
or 25 mg biweekly as induction dose, but no direct 
comparisons were found. PASI75 percentage ranges 
were similar, and thus an aggregation of all PASI75 
percentages is presented here. 
Ten studies (13, 18, 23, 25, 29–33, 35) reported long-
term results. No prospective studies reported solely on 
etanercept monotherapy. In 15 studies it was reported 
whether a combination therapy with a conventional sys-
temic agent was prescribed and the percentages ranged 
from 0% to 69% (13, 18–20, 22, 24, 27, 28, 30–35, 40). 
When combination therapy was allowed, methotrexate 
was used most often. Eight articles studied the licensed 
dosing of etanercept in (part of) the study and 12 studies 
(13, 18, 19, 22–25, 27, 29, 32, 33, 35) mentioned the 
ability for physicians to adjust the dose, but did not 
always provide a detailed description. Nine to 26% 
(18, 23, 27, 29, 33) of patients had their dose adjusted 
to 50 mg biweekly during maintenance treatment and 
3 studies reported a mean weekly dose of etanercept: 
64.1 mg (35), 68.3 mg (32) and 73.4 mg (13). 
PASI75 outcome for etanercept. Overall, PASI75 was 
attained by 12–66% with short-term, 19–85% with 
intermediate-term, and 49–92.3% with long-term (1- 
and 2-year) etanercept treatment.
Etanercept monotherapy. Retrospective studies repor-
ted a PASI75 of 36.1–54.1 (21, 31) at week 12, 66% 
(25) at week 16 and 60.5–85% (21, 25, 29, 31) at week 
24. At 1 year PASI75 was 71.4–92.3% (25, 29, 31) and 
at 2 years 86.9% (31).
Cohorts using etanercept with conventional systemic 
treatments. In prospective studies, etanercept achieved 
a PASI75 in 12–63% (13, 18, 22, 26, 32, 33) at week 
12 and 19–73.2% (13, 24, 26, 32, 33, 35) at week 24 in 
prospective studies and 25–69.2% (13, 32, 33, 35) at 1 
year. In retrospective studies 21.4–26% (19, 27, 30, 34) 
of patients achieved PASI75 at week 12, 37–53% (23, 
27, 30, 34) at week 24, and 49–54% (23, 30) at one year.
Dosing of etanercept. Of the 8 articles studying the 
licensed dosing of etanercept in (part of) the study, 
20–43% and 50–73.2% of patients achieved PASI75 at 
short- and intermediate-term, respectively (Table SIII1). 
Infliximab
Study characteristics. Four articles were included, 2 
prospective (18, 36) and 2 retrospective studies (40, 
41), including a total of 215 patients starting on inflixi-
mab. Two of 4 articles (36, 40) reported on infliximab 
monotherapy. Except for one study (18), all studies 
prescribed the licensed dose of infliximab. No study 
mentioned long-term results for PASI75. Combination 
therapy with a conventional systemic was prescribed 
in 5% (18) and 81% (41) of patients. Methotrexate 
was used most often. In 2 studies (18, 41) physicians 
decreased the dose interval (=dose increase) of inflixi-
mab in 10–23% of patients.
PASI75 outcome for infliximab. Overall, PASI75 was 
attained by 38–53% at short-term and 69% at interme-
diate-term treatment with infliximab.
Infliximab monotherapy. There were no PASI75 results 
from studies at week 12, 24 or on long-term treatment 
with infliximab monotherapy. At week 28, PASI75 was 
69% (36) in one prospective study.
Cohorts using infliximab with conventional systemic 
treatments. In the prospective study with combination 
therapy and dose adjustment (18), 38% of the patients 
who previously used biologics and 53% of biologic 
naïve patients reached PASI75 at week 12. 
Ustekinumab
Study characteristics. Four articles described results for 
ustekinumab; 2 prospective (36, 37) and 2 retrospec-
tive studies (38, 39), including a total of 315 patients 
starting on ustekinumab. Both prospective studies (36, 
37) reported on ustekinumab monotherapy. In all but 
one article (39) a licensed dose of ustekinumab was 
prescribed. One retrospective study (38) showed long-
term results. Combination therapy with a conventional 
systemic was prescribed in 9–14% (38, 39) of patients 
and methotrexate was used most often. In one study 
(39) the dose interval of ustekinumab was adjusted 
(dose increase) in 8% of treated patients due to a partial 
relapse several weeks prior to the next injection.
PASI75 outcome for ustekinumab. Overall, PASI75 
was attained by 63–80% at short-term, 58–75.9% at 
intermediate-term, and 65.5% at long-term (1 year 
data) with ustekinumab treatment.
Ustekinumab monotherapy. Prospectively, PASI75 
was attained by 80% (37) of patients at week 16 and 
58% (36) at week 28 with ustekinumab monotherapy. 
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Cohorts using ustekinumab with conventional systemic 
therapy. Two retrospective studies, of which one (39) 
was with dose adjustments, were included and pre-
sented a PASI75 of 79.3% (39) at week 12 and 63% 
(38) at week 16, 66.7–75.9% (38, 39) at week 24, and 
65.5% (39) at 1 year.
Naïve vs. non-naïve patients treated with biologics
Only a minority of included articles tried to assess the 
difference in biologic response between naïve and non-
naïve patients, but in most of these articles baseline 
PASI score between both groups was not compared. 
In only 3 articles (2 adalimumab and 1 ustekinumab) 
(16, 17, 39) it was stated that baseline PASI score was 
comparable between groups. For adalimumab, biologic 
naïve patients seemed to respond better compared with 
non-naïve patients, as measured with PASI75 at certain 
time-points and for ustekinumab the same phenome-
non was found for anti-tumour necrosis factor alpha 
(TNF-α) naïve and non-naïve patients. 
Conventional systemic therapies
Four articles (40, 42–44) reported on conventional sys-
temic treatment. One article was prospective (43) and 
3 retrospective (40, 42, 44). No articles were included 
on combination of 2 conventional systemic agents as 
this was an exclusion criteria in order to explore the 
true effectiveness of conventional systemic agents in 
daily practice. Except for one study on methotrexate 
(40), all studies reported a mean PASI score above 
10 at start of treatment (11.6–26.5), which represents 
patients with moderate to severe psoriasis.
Acitretin
Study characteristics. One retrospective study (42) 
including 62 patients starting on acitretin was included. 
No prospective studies were available.
Monotherapy. In one retrospective study, PASI75 
response was attained by 27% (42) of patients with a 
mean dose of 0.38 mg/kg/day at week 12. No prospec-
tive or retrospective data were available on long-term 
treatment with acitretin.
Fumarates
Study characteristics. Two articles (43, 44) reported the 
effectiveness of fumarates in daily practice, including 
a total of 312 patients starting on fumarates. One study 
(43) was prospective and one (44) was retrospective. 
In one study (43) a maximum daily dose of 360 mg 
was prescribed at week 6 and in the other study (44) 
this was 720 mg at week 9.
Monotherapy. One retrospective study showed a 
PASI75 of 47% (44) at week 12, 63% (44) at week 
24, and 76% (44) at 1 year. No long-term results from 
prospective studies were available.
Cyclosporine
Study characteristics. One retrospective article (42) stu-
died the effectiveness of cyclosporine in daily practice, 
including a total of 36 patients starting on cyclosporine. 
In this study, a mean dose of 3.5 mg/kg/day was given. 
Monotherapy. In one retrospective study, 46% (42) of 
patients reached a PASI75 at week 12.
Methotrexate
Study characteristics. Three articles (40, 42, 44) stu-
died the effectiveness of methotrexate in daily prac-
tice, including 189 patients starting on methotrexate. 
All studies were retrospective. In one study (40) the 
methotrexate dose was 15 mg weekly and was given 
intramuscularly. In another study (44) methotrexate 
initial dose of 10 mg once weekly was increased to a 
maximum of 20 mg once weekly. Piaserico et al. (42) 
gave methotrexate in a mean weekly dose of 11.7 mg.
Monotherapy. In the retrospective studies, between 
40% and 49% (42, 44) of patients treated with metho-
trexate 10–20 mg weekly achieved PASI75 at week 
12 and 62% (44) at week 24. Eighty-one percent (44) 
achieved PASI75 at 1 year. No prospective data were 
available.
Comparative studies
Three retrospective studies (40, 42, 44) and 2 prospec-
tive studies (18, 36) compared anti-psoriatic agents 
within the study. Piaserico et al. (42) showed that the 
proportion of patients achieving PASI75 with acitretin 
(27%) was significantly lower than that of patients 
treated with methotrexate (49%, p = 0.01), etanercept 
(64%, p < 0.0001), adalimumab (65%, p < 0.01) and 
infliximab (93%, p < 0.001) at week 12. Mean baseline 
PASI score appeared similar between these treatments 
(methotrexate: 12.7; acitretin 14.8; etanercept 14.9; 
adalimumab 14.3; infliximab 14.8). Inzinger et al. (44) 
showed that, when prescribed as a primary treatment, 
the effectiveness of methotrexate was similar to that of 
fumarates; however, the mean PASI at start of metho-
trexate (18.3) was higher than for fumarates (11.6). 
In this study, no significance tests were performed 
for baseline variables. Gisondi et al. (40) compared 
mean PASI decrease between methotrexate, etaner-
cept and infliximab at week 24. Mean PASI decrease 
was significantly higher for infliximab compared with 
methotrexate, infliximab compared with etanercept, 
and etanercept compared with methotrexate. Patients 
treated with etanercept or infliximab, however, had 
higher baseline PASI scores compared with patients 
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receiving methotrexate (p = 0.0001). Between eta-
nercept and infliximab treated patients, there was no 
significant difference in baseline PASI score (p = 0.6). 
The prospective study of Gisondi et al. (36) showed 
no significant differences between ustekinumab and 
infliximab for mean PASI decrease at weeks 4 and 28. 
Mean baseline PASI scores did not differ between these 
2 groups (p = 0.1). The prospective study of Menting 
et al. (18) showed no significant difference in mean 
change in PASI scores between adalimumab, etanercept 
and infliximab at weeks 12 and 24. Baseline PASI did 
not differ between the 3 groups.
DISCUSSION
To our knowledge, this is the first systematic review on 
effectiveness in daily practice of biologics (etanercept, 
adalimumab, infliximab and ustekinumab) and conven-
tional systemic agents (acitretin, cyclosporine, fumara-
tes and methotrexate). Effectiveness data from real-life, 
observational studies are of added value, since patients 
and treatment strategies in daily practice substantially 
differ from those in RCTs (8). A substantial proportion 
of patients were achieving PASI75 with short- (week 
12–16), intermediate- (17–28) and long-term (≥ 1 year) 
treatment with biologics and conventional systemic 
agents, except for acitretin monotherapy. 
At short-term, PASI75 was 35–68% for adalimumab, 
12–66% for etanercept, 38–53% for infliximab, 63–80% 
for ustekinumab, 27% for acitretin, 47% for fumarates, 
46% for cyclosporine and 40–49% for methotrexate. At 
long-term (1- and 2-year data), PASI75 was 44–89% 
for adalimumab, 49–92.3% for etanercept, 65.5% for 
ustekinumab, 76% for fumarates and 81% for metho-
trexate. We encountered a high heterogeneity in study 
design (prospective/retrospective), treatment regimen 
(e.g. dose adjustments, combination with conventional 
systemic agents) and patient population (e.g. baseline 
PASI scores, naïve/non-naïve) especially in studies on 
biologic treatments. Possible explanatory factors for 
the large ranges in PASI75 percentages, especially in 
etanercept and adalimumab therapy, were the use of 
combination strategies with a conventional systemic 
agent and dose adjustments.
In most studies on biologic therapies, concomitant 
conventional systemic agents were allowed and pres-
cribed by physicians (24/29 studies). Methotrexate was 
mostly prescribed as combination therapy. In these 
studies, data were not analysed separately for patients 
using combination therapy. Therefore, we reported 
studies on combination therapy separately, but found 
similar PASI75 ranges between monotherapy and com-
bination therapy. There is some evidence from RCTs 
on combining biologics with conventional agents, with 
most data for etanercept combined with methotrexate 
(45). In daily clinical practice, however, combination 
strategies are often applied in case of ineffectiveness, 
and may explain the similar results found in patients 
with and without combination therapies. More studies 
are needed into combination therapy of conventional 
systemic agents with biologic therapies.
Another explanation for the heterogeneity in study 
results is that dosing regimens differed between studies, 
especially for etanercept and adalimumab treatment. 
In adalimumab studies, all articles described dose in-
creases and in studies with etanercept in more than half 
of included studies a dose increase was allowed. Afore-
mentioned PASI75 results were therefore achieved with 
higher doses than licensed dose. Dose adjustments were 
less common in studies on infliximab and ustekinumab, 
although the number of included articles was too small 
to draw definitive conclusions. If this is indeed the case, 
dose adjustments could lead to higher costs for biologic 
treatment with etanercept and adalimumab compared 
with infliximab and ustekinumab.
Heterogeneity is typical in treating real-life patients 
and is not studied in RCTs. The results from daily prac-
tice studies enrich the body of evidence and can be of 
added value to current data from RCTs and guidelines 
when the quality of data reporting is improved. In or-
der to improve this quality, it is strongly advised that 
authors of future studies report the items included in 
the STROBE statement (46). The following issues are 
of particular importance: study design (prospective, 
retrospective, wash-out period and method of analysis); 
and patient characteristics (age, sex, body weight, 
baseline PASI score, duration of psoriasis, previous 
treatments, presence of psoriatic arthritis, number of 
patients with and treatment duration of combinations of 
systemic anti-psoriatic therapies and dosages used). In 
case of biologic treatment in particular, it is important 
to describe naivety to biologics, previous biologic 
therapies, and dosing regimens.
Comparative studies were scarce and were hampered 
by differences at treatment start. Some RCTs (47–51) 
compared agents head-to-head. Data from pragmatic 
randomized daily practice studies or comparative ef-
fectiveness studies adjusted for confounders could be 
informative and decrease this gap in the evidence in 
the literature.
In conclusion, biologic and conventional systemic 
agents are effective in daily practice. Combination thera-
pies of biologics with conventional systemic treatments 
and dose adjustments of biologics were frequently app-
lied strategies, especially for adalimumab and etanercept, 
and could explain the large ranges in PASI75 results. 
There was a high heterogeneity in study design, treatment 
regimen and patient population between included studies. 
We made recommendations in order to improve the qua-
lity of reporting in daily practice studies. Gaps identified 
were daily practice data on infliximab, ustekinumab, 
conventional systemic therapies, long-term treatment, 
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combination therapy and results of direct comparisons 
on effectiveness between anti-psoriatic agents.
The authors declare no conflicts of interest.
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